Survey: Erbitux now standard of care for confirmed KRAS Wild-Type mCRC - MENAFN

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service21 times read : Adjust font size: Decrease font Enlarge font
image

... treatment with Erbitux Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that survey results published at this year’s American Society of Clinical Oncology (ASCO ... growth factor receptor (EGFR). As a monoclonal ...

Read this article...



Post your comment comment Comments (0 posted)

More News

copyright